Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999187 · ClinicalTrials.gov registry record · Phase 1
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Dren Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 10
- Study locations
NCT06999187 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is actively recruiting participants, run by Dren Bio. The registered enrollment target is 96 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT06999187, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Dren Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 10
- Study locations
Study Summary
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Conditions Studied
Interventions
- DRUG DR-0202
Study Locations (10)
Texas
- Dren Investigational Site - Austin
- Dren Investigational Site - Dallas
- Dren Investigational Site - San Antonio
Florida
- Dren Investigational Site - Orlando
- Dren Investigational Site - Sarasota
Colorado
- Dren Investigational Site - Denver
North Carolina
- Dren Investigational Site - Huntersville
Oklahoma
- Dren Investigational Site - Oklahoma City
South Carolina
- Dren Investigational Site - Greenville
Virginia
- Dren Investigational Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06999187
The ClinicalTrials.gov registry entry for NCT06999187 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Dren Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which DR-0202 is the first listed.
NCT06999187 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Texas, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06999187 about?
NCT06999187 is a clinical study titled "A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas". A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
What is the current status of trial NCT06999187?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2025-06-03. Estimated completion is 2027-12.
What conditions does trial NCT06999187 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Cervical Cancer.
What interventions are being tested in trial NCT06999187?
The interventions under investigation include: DR-0202 (DRUG).
Who is sponsoring clinical trial NCT06999187?
This trial is sponsored by Dren Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999187 being conducted?
This trial has 10 study locations across Colorado, Florida, North Carolina, Oklahoma, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.